|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents ($160,967 and $171,047 restricted at December 31, 2018 and September 30, 2019, respectively) | ||||||||||||||||||||
| Cash and cash equivalents ($49,227 and $79,746 restricted at December 31, 2020 and September 30, 2021, respectively) | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Short-term investments ($88,867 and $101,884 restricted at December 31, 2020 and September 30, 2021, respectively) | ||||||||||||||||||||
| Pharmaceutical inventory | ||||||||||||||||||||
| Other current assets ($43,547 and $74,385 restricted at December 31, 2020 and September 30, 2021, respectively) | ||||||||||||||||||||
| Current portion of assets held for sale | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Long-term investments ($1,026 and $0 restricted at December 31, 2020 and September 30, 2021, respectively) | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Assets held for sale, less current portion | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Short-term contingent consideration | ||||||||||||||||||||
| Medical claims payable | ||||||||||||||||||||
| Other medical liabilities | ||||||||||||||||||||
| Current debt, finance lease and deferred financing obligations | ||||||||||||||||||||
| Current portion of liabilities held for sale | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term debt, finance lease and deferred financing obligations | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Tax contingencies | ||||||||||||||||||||
| Long-term contingent consideration | ||||||||||||||||||||
| Deferred credits and other long-term liabilities | ||||||||||||||||||||
| Liabilities held for sale, less current portion | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Redeemable non-controlling interest | ||||||||||||||||||||
| Stockholder's Equity: | ||||||||||||||||||||
| Common stock, par value $.01 per share: Authorized-100,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-55,549 and 25,887 shares at December 31, 2020, respectively, and 55,994 and 26,332 shares at September 30, 2021, respectively | ||||||||||||||||||||
| Total common stock, par value $.01 per share: Authorized-100,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-55,549 and 25,887 shares at December 31, 2020, respectively, and 55,994 and 26,332 shares at September 30, 2021, respectively | ||||||||||||||||||||
| Other Stockholders' Equity: | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost, 29,662 and 29,662 shares at December 31, 2020 and September 30, 2021, respectively | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities, Redeemable Non-Controlling Interest and Stockholders' Equity | ||||||||||||||||||||
Loading...